Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4360452 | PMC |
http://dx.doi.org/10.4103/0971-9261.151563 | DOI Listing |
AAPS J
November 2020
Pharmaceutical Sciences, Roche Innovation Center Basel, F.Hoffmann-La Roche Ltd. Grenzacherstrasse 124, 4070, Basel, Switzerland.
During production, the figure captions for Fig. 1 and Fig. 2 were inadvertently switched in the proofing stage.
View Article and Find Full Text PDFCase Rep Urol
March 2019
Pediatric Urology Division, Pediatric Surgery Department, Maternity and Children Hospital, Makkah, Saudi Arabia.
Congenital absence of the vas deferens (CAVD) is an uncommon anomaly that occurs in up to 1% of the male population. It can be associated with various other anomalies, including cryptorchidism and renal anomalies, such as renal agenesis. We here present a case of cryptorchidism with ipsilateral congenital absence of the vas deferens and renal agenesis and used the Stephen-Fowler technique for Orchiopexy depending on gubernacular vessels.
View Article and Find Full Text PDFJ Indian Assoc Pediatr Surg
April 2015
Department of Pediatric Surgery, Seth Gordhandas Sunderdas Medical College and King Edward Memorial Hospital, Mumbai, Maharashtra, India.
J Laparoendosc Adv Surg Tech A
March 2010
Department of Pediatric Surgery, King Edward Memorial Hospital, Mumbai, India.
Unlabelled: The length of testicular vessels is the main length-limiting factor to bring down the testes in the scrotum. Fowler and Stephen proposed the division of testicular vessels, high and as far from the testes as possible to maintain collateral blood supply, to treat high intra-abdominal testes. Cortesi introduced the diagnostic laparoscopy and Jorden first did the laparoscopic orchiopexy for nonpalpable testes.
View Article and Find Full Text PDFAAPS J
June 2008
Drug Metabolism and Pharmacokinetics, F. Hoffmann La-Roche Ltd., 4070, Basel, Switzerland.
It is widely accepted that today's practice of polypharmacy inevitably increases the incidence of drug-drug interactions (DDIs). Serious DDI is a major liability for any new chemical entity (NCE) entering the pharmaceutical market. As such, pharmaceutical companies employ various strategies to avoid problematic compounds for clinical development.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!